Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.
UPS cuts outlook, Moody's downgrades U.S. banks, Eli Lilly raises guidance: Aug 8, 2023
Yahoo Finance anchor Julie Hyman breaks down three things to know for August 8, 2023 including UPS earnings, Moody's downgrading U.S. banks, and Eli Lilly raising guidance.
Call Traders Blast Ely Lilly Stock Amid Post-Earnings Peak
The shares of Eli Lilly And Co (NYSE:LLY) are trading at record highs today, last seen up 16% at $522.45, following a blockbuster trip to the earnings confessional.
Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates
Eli Lilly (LLY) came out with quarterly earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.25 per share a year ago.
Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts
The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that c...
Dow seen lower as Moody's hits banks but Eli Lilly set to fly
7.50am: Banks hit by Moody's downgrades, Eli Lilly ups guidance US stocks are expected to open lower with banks under pressure after Moody's downgraded ratings for a number of small to mid-sized le...
Eli Lilly stock up in premarket as Mounjaro diabetes drug sales surge
Eli Lilly and Co (NYSE:LLY) stock is seen higher ahead of Tuesday's open after reporting a strong, expectation-beating, second-quarter performance led by type-2 diabetes drug Mounjaro. Revenue for ...
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising obesity drug pipeline.
Eli Lilly beats profit estimates on strength of new diabetes drug
Eli Lilly beat Wall Street estimates for second-quarter profit on Tuesday, buoyed by strong demand for its new diabetes drugs Mounjaro, ahead of a decision on the medicine's use as a weight-loss tr...
Related Companies